Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.

Blood
Kathryn G RobertsStephen P Hunger

Abstract

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL; BCR-ABL1-like ALL) in children with National Cancer Institute (NCI) intermediate- or high-risk (HR) ALL is associated with poor outcome. Ph-like ALL is characterized by genetic alterations that activate cytokine receptor and kinase signaling and may be amenable to treatment with tyrosine kinase inhibitors. The prevalence, outcome, and potential for targeted therapy of Ph-like ALL in standard-risk (SR) ALL is less clear. We retrospectively analyzed a cohort of 1023 SR childhood B-ALL consecutively enrolled in the Children's Oncology Group AALL0331 clinical trial. The Ph-like ALL gene expression profile was identified in 206 patients, and 67 patients with either BCR-ABL1 (n = 6) or ETV6-RUNX1 (n = 61) were excluded from downstream analysis, leaving 139 of 1023 (13.6%) as Ph-like. Targeted reverse transcription polymerase chain reaction assays and RNA-sequencing identified kinase-activating alterations in 38.8% of SR Ph-like cases, including CRLF2 rearrangements (29.5% of Ph-like), ABL-class fusions (1.4%), JAK2 fusions (1.4%), an NTRK3 fusion (0.7%), and other sequence mutations (IL7R, KRAS, NRAS; 5.6%). Patients with Ph-like ALL had inferior 7-year event-fre...Continue Reading

References

Jan 9, 2009·The New England Journal of Medicine·Charles G MullighanUNKNOWN Children's Oncology Group
Dec 19, 2009·Proceedings of the National Academy of Sciences of the United States of America·Akinori YodaDavid M Weinstock
Jul 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brent W WestonCharles G Mullighan
Jul 23, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathryn G RobertsChing-Hon Pui
Sep 11, 2014·The New England Journal of Medicine·Kathryn G RobertsCharles G Mullighan
Oct 16, 2015·The New England Journal of Medicine·Stephen P Hunger, Charles G Mullighan
Feb 10, 2016·Cancer Cell·Ilaria IacobucciCharles G Mullighan
Jul 20, 2016·EBioMedicine·Yuan-Fang LiuSai-Juan Chen
Sep 17, 2016·Haematologica·Shinsuke HirabayashiUNKNOWN Tokyo Children’s Cancer Study Group (TCCSG)
Nov 1, 2016·Nature Genetics·Jinghui ZhangUNKNOWN St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project
Nov 9, 2016·Nature Communications·Zhaohui GuCharles G Mullighan
Nov 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathryn G RobertsCharles G Mullighan
Nov 29, 2016·Oncotarget·Judith M BoerMonique L den Boer
Dec 7, 2016·Blood·Nitin JainMarina Konopleva
Dec 30, 2016·Genes, Chromosomes & Cancer·Lisa J RussellChristine J Harrison
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ilaria Iacobucci, Charles G Mullighan
Aug 6, 2017·Blood·Henrik Lilljebjörn, Thoas Fioretos
Oct 4, 2017·Blood·Sarah K TasianStephen P Hunger
Nov 23, 2017·Oncotarget·Elisabeth M P SteeghsMonique L den Boer

❮ Previous
Next ❯

Citations

Dec 7, 2018·Hematology·Kathryn G Roberts
Dec 29, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine M AlbertTheodore W Laetsch
May 10, 2019·International Journal of Laboratory Hematology·Joanna L Conant, David R Czuchlewski
Apr 20, 2020·Genes, Chromosomes & Cancer·Andrea BiloglavBertil Johansson
Oct 28, 2019·Cold Spring Harbor Perspectives in Medicine·Kathryn G Roberts, Charles G Mullighan
May 18, 2020·Haematologica·Gunnar CarioAndrea Biondi
Mar 20, 2020·The Journal of Clinical Investigation·Christian HurtzSarah K Tasian
Dec 19, 2018·Cancer·Sabina ChiarettiRobin Foà
Apr 3, 2020·International Journal of Molecular Sciences·Parveen ShirazLori Muffly
Oct 20, 2020·Frontiers of Medicine·Ching-Hon Pui
Feb 17, 2019·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Lindsay A WilliamsLogan G Spector
Jan 25, 2021·Clinical Lymphoma, Myeloma & Leukemia·Vineeta YadavDinesh Kumar V
Dec 22, 2020·Terapevticheskiĭ arkhiv·K I ZarubinaV G Savchenko
Oct 8, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ibrahim AldossVinod Pullarkat
May 6, 2021·Journal of Clinical Medicine·Hiroto Inaba, Ching-Hon Pui
Aug 12, 2021·NPJ Precision Oncology·Charlotte E J DownesDeborah L White

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Kathryn G RobertsCharles G Mullighan
The New England Journal of Medicine
Kathryn G RobertsCharles G Mullighan
Best Practice & Research. Clinical Haematology
Kathryn G Roberts
© 2022 Meta ULC. All rights reserved